



RPG LIFE SCIENCES LIMITED
Unit No. 208-213, B Wing,
Bezzola Complex,
Sion-Trombay Road, Chembur,
Mumbai 400071, India
Tel: +91-22-25292152-55
Fax: +91-22-25297423

July 28, 2021

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C-1, G- Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers,
Dalal Street,
Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter ended June 30, 2021.

Kindly take the above on record.

Thanking you,

Yours Sincerely,
For RPG Life Sciences Limited



Rajesh Shirambekar
Head – Legal & Company Secretary

Encl.: as above



**Q1 FY22 Revenue from operations grew by 18% Y-o-Y and 17% Q-o-Q.
PBT grew by 50% Y-o-Y and 115% Q-o-Q.**

Mumbai, 28 July, 2021: RPG Life Sciences Limited has announced its financial results for the quarter ended June 30, 2021.

Q1 FY22 Highlights	Y-o-Y Revenue from operations	Y-o-Y PBT
	Rs 108.13 crores – up from Rs 91.65 crores	Rs 19.27 crores – up from Rs 12.83 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in profits by 50% Y-o-Y and by 115% Q-o-Q for Q1 FY22, maintaining the upward trajectory in EBITDA margins, which improved from 18.9% to 21.6% Y-o-Y. Revenue from operations at Rs 108.13 crores registered a growth of 18% Y-o-Y and a growth of 17% Q-o-Q for Q1 FY22.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q1 FY22, the overall performance of the Company continued to be strong despite the impact of the second wave of COVID-19 pandemic. Revenue and PBT grew by 18% and 50% respectively Y-o-Y. EBITDA margin retained its upward trajectory growing from 18.9% to 21.6% Y-o-Y.

We continue to be focused on executing our turnaround strategy. On domestic business front, it comprises of 5 initiatives viz. Product portfolio rejuvenation by building chronic and specialty portfolio with new launches; Building our strategic brand assets through diligent life cycle management strategies; Deepening our customer coverage in targeted therapies by expanding our field force and increasing our Share of Voice through innovative digital solutions; Strengthening our Prescription Business model by focusing on all customer, salesforce and patient related initiatives; and Improving profitability by opex control, efficient manufacturing operations and sales hygiene. On international business front, our strategy is to step-wise build up our business profitably with a focus on expanding markets and products with some competitive edge.”

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

RPG Enterprises, established in 1979, is one of India’s fastest growing business groups with a turnover of US\$ 4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

Media Contact:

Sumeet Chatterjee

Senior Vice President – Corporate Brand and Group Communications

+91 9820340650 | sumeet@rpg.in

